Nanopath announced that it closed a Series A funding round to support its biosensing platform for diagnostics.
Cambridge, Massachusetts–based Nanopath intends to use the funds to back the development and commercialization of its platform that aims to transform how women’s pelvic and gynecologic infections are diagnosed. The company designed its novel approach to simultaneously characterize multiple pathogens with one test for faster, more precise diagnosis and treatment.
Nanopath’s proprietary biosensing technology uses ultrasensitive optical detection to identify DNAs and RNAs without the need for nucleic acid amplification. The approach minimizes reagents, lowers costs and reduces user steps while requiring minimal training to operate, making them accessible at the point of care.
According to a news release, Norwest Venture Partners and the Medtech Convergence Fund, a SV Health Investors venture fund, led the financing round. Ging…